After receiving FDA breakthrough therapy status for its lead candidate in July, gene therapy company AveXis has released promising new safety and efficacy data. AVXS-101 is being developed to ...
Last year’s additions included gene therapy company AveXis, bought for $8.7 billion, and radiotherapy specialists Endocyte which cost $2.1 billion, and Narasimhan said there was an appetite in ...
At AveXis, a Novartis company, we have built on 30 years of science to deliver on this challenge by demonstrating the long-term curative potential of gene therapy and its capacity to make an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback